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Early and accurate identification of people at high risk of premature death may assist in the targeting of preventive
therapies in order to improve overall health. To identify novel biomarkers for all-cause mortality, we performed
untargeted metabolomics in the Atherosclerosis Risk in Communities (ARIC) Study. We included 1,887 eligible
ARIC African Americans, and 671 deaths occurred during a median follow-up period of 22.5 years (1987–2011).
Chromatography and mass spectroscopy identified and quantitated 204 serum metabolites, and Cox proportional
hazards models were used to analyze the longitudinal associations with all-cause and cardiovascular mortal-
ity. Nine metabolites, including cotinine, mannose, glycocholate, pregnendiol disulfate, α-hydroxyisovalerate,
N-acetylalanine, andro-steroid monosulfate 2, uridine, and γ-glutamyl-leucine, showed independent associations
with all-cause mortality, with an average risk change of 18% per standard-deviation increase in metabolite level
(P < 1.23 × 10−4). A metabolite risk score, created on the basis of the weighted levels of the identified metabolites,
improved the predictive ability of all-cause mortality over traditional risk factors (bias-corrected Harrell’s C statistic
0.752 vs. 0.730). Mannose and glycocholate were associated with cardiovascular mortality (P < 1.23 × 10−4), but
predictive ability was not improved beyond the traditional risk factors. This metabolomic analysis revealed potential
novel biomarkers for all-cause mortality beyond the traditional risk factors.
all-cause mortality; cardiovascular mortality; metabolomics; risk factors
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio;
SD, standard deviation.
All-causemortality is a traditional measure of overall disease
burden in public health, and currently, cardiovascular disease
(CVD) is the leading age-adjusted cause of death in the United
States (1). Early and accurate identification of people at high
risk of premature death, particularly CVD-related death, could
assist in the targeting of preventive therapies in order to im-
prove overall health. Previous studies have shown that levels
of circulating biomarkers have the potential to predict all-cause
mortality and CVD mortality (2–7). However, there remains
considerable unexplained risk, and a systematic way to fully
explore the effect of many circulating molecules is lacking.
Metabolomics, which characterizes small-molecule metabo-
lites produced by a variety of biochemical and cellular process-
es, takes us a step closer to this ideal and is one path toward
new biomarker discovery. By using targeted metabolomic
technology, Fischer et al. (8) recently identified 4 metabolites
(out of 106) that are associated with all-cause and CVD mor-
tality among the Estonian and Finnish populations, but the
majority of the targeted metabolites (e.g., 85 of the 106)
were lipids. Therefore, the predictive ability of the untargeted
metabolome, consisting of many metabolites in other catego-
ries, remains unclear.
Untargeted metabolomic technologies capture numerous
small molecules in a biosample representing multiple path-
ways and functional classes, and thus provide the opportunity
to more fully assess relationships between diverse metabo-
lites and mortality. African-American adults have higher
rates of all-cause mortality and CVD mortality than other
US racial/ethnic groups (9), but the exact mechanism under-
lying such disparity is not clear. To date, no study appears to
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have explored the metabolomic antecedents of all-cause and
CVD mortality in a large African-American population. In
a well-characterized, population-based sample of African
Americans from the Atherosclerosis Risk in Communities
(ARIC) Study, we explored the longitudinal association of the
serum metabolome, quantified by means of untargeted me-
tabolomic technology, with all-cause mortality and CVD
mortality after a median of 22.5 years of follow-up.
METHODS
Study population
The ARIC Study is a prospective cohort study designed to
investigate the etiology and predictors of CVD. The ARIC
Study enrolled 15,792 adults from 4 US communities (Forsyth
County, North Carolina; Jackson, Mississippi; selected sub-
urbs of Minneapolis, Minnesota; and Washington County,
Maryland) between 1987 and 1989. A detailed description
of the ARIC Study’s design and methods has been published
elsewhere (10). Metabolomic profiles were measured in 1,977
African Americans from the Jackson field center, and among
them, 1,887 participants with complete mortality follow-up in-
formation and covariates were included in this study.
Cause of death for study participants was ascertained through
annual cohort follow-up, community-wide hospital surveil-
lance, and linkage with local and national death registries.
The date and cause of death were verified by death certificate
review. All-cause mortality was defined as death from any
cause, and CVD mortality was defined as any death in which
the principal cause was cardiovascular in nature, using Inter-
national Classification of Diseases, Ninth Revision, codes
390–459 or International Classification of Diseases, Tenth
Revision, codes I00–I99. For this analysis, the vital status
of study participants was followed from baseline through De-
cember 31, 2011.
For covariates, demographic information was obtained
during an in-home interview. Hypertension was defined as
systolic blood pressure ≥140 mm Hg, diastolic blood pres-
sure ≥90 mm Hg, or use of antihypertensive medication. An-
tihypertensive medication use was recorded by self-report
and ascertained by inventory. Diabetes was defined as fasting
glucose concentration ≥126 mg/dL, nonfasting glucose con-
centration≥200 mg/dL, a self-report of a physician’s diagno-
sis of diabetes or “sugar in the blood,” or use of oral diabetes
medication or insulin. Prevalent CVD was defined by evi-
dence of prior myocardial infarction, heart failure, or stroke,
history of physician-diagnosed heart attack, or previous coro-
nary reperfusion procedure. Smoking status was self-reported
and was categorized as current smoker or non–current smoker.
Plasma total cholesterol and high-density lipoprotein cholesterol
concentrations were determined by standardized enzymatic
methods. Estimated glomerular filtration rate was calculated
using the Chronic Kidney Disease Epidemiology Collabora-
tion equation (11).
Measurement of the metabolome
Metabolite profiling was measured using baseline fasting
serum samples that had been stored at −80°C since collection.
More than 600 metabolites were detected and quantified
by Metabolon, Inc. (Durham, North Carolina) using an un-
targeted metabolomic quantification protocol based on gas
chromatography–mass spectrometry and liquid chromatogra-
phy–mass spectrometry (12, 13). Metabolites were excluded
from this analysis if 1) more than 80% of the samples had val-
ues below the detection limit or 2) the reliability coefficient,
based on a comparison of 2 samples from 60 individuals
collected 4–6 weeks apart, was less than 0.60. After these ex-
clusions, 204 metabolites, including 118 named compounds
within 8 super-pathways (including amino acids, carbohy-
drates, vitamins, energy, lipids, nucleotides, peptides, and xe-
nobiotics) and 86 unnamed compounds, were involved and
analyzed in this study. The unnamed compounds were as-
signed tags beginning with “X” and followed by numbers
(e.g., “X-12345”).
Statistical analysis
Out of 204metabolites, 187 had values above the detection
limit in at least 50% of the samples and were analyzed as con-
tinuous variables, where “below detection” values were im-
puted as the lowest detected value for that metabolite in all
samples. After imputation, each of the 187 metabolites was
centered by its mean and scaled by its standard deviation
prior to the analysis. The other 17 metabolites with 50%–80%
“below detection” values were analyzed as ordinal variables
with 3 levels: 1) values below the detection limit, 2) detected
values below the median of all “above detection” values,
and 3) detected values at or above the median.
We assessed the longitudinal associations of metabolite
levels with all-cause mortality and CVD mortality using Cox
proportional hazards models, with adjustment for age, sex,
and traditional risk factors, including body mass index, sys-
tolic blood pressure, antihypertensive medication use, diabe-
tes status, prevalent CVD, current smoking status, estimated
glomerular filtration rate, and total cholesterol and high-
density lipoprotein cholesterol levels. The proportional haz-
ards assumption was tested using the methods developed by
Grambsch and Therneau (14). Statistical significance at this
stagewas defined asP < 1.23 × 10−4, accounting for testing of
204 metabolites and 2 outcomes using Bonferroni correction.
Because of the potential correlation between metabolites,
we next evaluated the independent associations of the sig-
nificant metabolites using a forward stepwise analysis of all-
cause mortality and CVD mortality. The metabolite with the
smallest P value identified in the Cox proportional hazards
model was included as a predictor, adjusting for traditional
risk factors as described above. Subsequently, the metabolite
with the next-smallest P value in the Cox proportional haz-
ards model was included as a predictor, adjusting for tradi-
tional risk factors and the first metabolite. The process was
repeated until no additional metabolite was significant at
P < 0.05.
Ametabolite risk score was generated by summing the lev-
els of independent mortality-related metabolites weighted by
the regression coefficients observed in the Cox model for
each individual metabolite. We divided the metabolite risk
scores into quartiles to estimate the associations with each
outcome using a Cox proportional hazards model adjusting
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for the same covariates as those described above. We inves-
tigated the ability of the model to predict risk using Harrell’s
C statistic (15, 16), for which the censoring distribution is
consideredwhen calculating the concordance probability.We
performed 10-fold cross-validation to derive a bias-corrected
Harrell’s C statistic and to obtain a more precise assessment
of model performance. In addition, we calculated the net re-
classification index and the integrated discrimination index
based on 20-year risk of death according to Pencina et al.
(17). Net reclassification index was assessed as a continuous
measure and as a categorical measure by assigning individu-
als to one of 3 risk categories (<6%, 6%–20%, and >20%).
Table 1. Baseline Characteristics of Participants by Mortality Status Among African Americans in the ARIC Study,
1987–2011
Characteristic
Type of Death Event
None All-Cause Mortality CVD Deaths Only
No. % Mean (SD) No. % Mean (SD) No. % Mean (SD)
Total 1,216 671 259
Age, years 51.5 (5.3) 55.3 (5.7) 55.6 (5.6)
Male sex 376 30.9 304 45.3 119 45.9
Diabetes 132 10.9 176 26.2 87 33.6
Prevalent CVD 76 6.3 117 17.4 62 23.9
Current smoking 269 22.1 277 41.3 104 40.2
Hypertension 568 46.7 442 65.9 205 79.2
Antihypertensivemedication use 416 34.2 308 45.9 148 57.1
Body mass indexa 29.7 (6.0) 29.6 (6.2) 30.5 (6.4)
HDL cholesterol, mg/dL 56.7 (16.8) 53.5 (17.7) 51.0 (15.3)
Total cholesterol, mg/dL 215.3 (45.0) 214.0 (44.9) 215.4 (45.8)
Serum-based eGFRCKD-EPI,
b
mL/minute/1.73 m2
106.1 (16.3) 100.6 (21.0) 98.8 (22.4)
Follow-up time, years 23.2 (1.1) 13.5 (6.6) 13.0 (6.5)
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density
lipoprotein; SD, standard deviation.
a Weight (kg)/height (m)2.
b eGFR was calculated using the CKD-EPI equation (11).
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Figure 1. Associations between 204 serum metabolites and incident all-cause mortality (A) and cardiovascular disease mortality (B), by metab-
olomic super-pathway, among African Americans in the Atherosclerosis Risk in Communities (ARIC) Study, 1987–2011. The x-axis shows 8 me-
tabolite super-pathways; the y-axis shows the common logarithm (log10) of the P value for each metabolite. The dotted gray line represents the
statistical significance threshold (P < 1.23 × 10−4).
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All statistical analyses were performed using R (R Develop-
ment Core Team, R Foundation for Statistical Computing,
Vienna, Austria (http://www.r-project.org)).
RESULTS
A total of 1,887 eligible ARICAfrican Americans were in-
cluded in this study, with a median follow-up period of 22.5
years. During the follow-up time period, there were 671
deaths in this study sample, and 259 of the 671 deaths were
from CVD. Baseline characteristics of the study sample by
mortality status are shown in Table 1. Male sex, prevalent di-
abetes, hypertension, prevalent CVD, current smoking, and
lower high-density lipoprotein cholesterol levels were indi-
vidually associated with death events.
Metabolomic association with all-cause mortality
We identified 18 metabolites (11 named and 7 unnamed)
among the 8 super-pathways that were significantly associ-
ated (P < 1.23 × 10−4) with incident all-cause mortality after
adjustment for demographic and traditional risk factors
(Figure 1A; full results are presented in Web Table 1, avail-
able at http://aje.oxfordjournals.org/). Higher levels were
associated with increased risk of death for 14 out of 18 me-
tabolites, and the other 4 metabolites appeared to have pro-
tective associations. Among the 11 named metabolites, the
pairwise correlation ranged from −0.21 to 0.64, and thus the
next step was to examine whether they had mutually indepen-
dent associations with all-cause mortality. Nine metabolites
showed independent associations, with an average risk change
All-cause mortality
Amino acid
N-acetylalanine
Nucleotide
Uridine
Peptide
γ-Glutamyl-leucine
Xenobiotic
Cotinine
Pregnendiol disulfate
Andro-steroid monosulfate 2
Glycocholate
Carbohydrate
Mannose
Cardiovascular mortality
Lipid
Glycocholate
Carbohydrate
Mannose
HR (95% CI)
1.14 (1.08, 1.20)
1.12 (1.06, 1.18)
0.86 (0.79, 0.92)
0.80 (0.74, 0.87)
1.40 (1.23, 1.59)
1.17 (1.10, 1.25)
1.13 (1.08, 1.19)
1.12 (1.07, 1.16)
1.22 (1.13, 1.31)
1.14 (1.07, 1.22)
1.33 (1.21, 1.47)
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Hazard Ratio
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α-Hydroxyisovalerate
Lipid
Figure 2. Hazard ratios (HRs) and 95% confidence intervals (CIs) for named serummetabolites predicting the risk of all-cause and cardiovascular
disease mortality among African Americans in the Atherosclerosis Risk in Communities (ARIC) Study, 1987–2011. HRs were estimated in Cox
models adjusting for age, sex, body mass index, systolic blood pressure, antihypertensive medication use, diabetes status, current smoking status,
prevalent cardiovascular disease status, plasma high-density lipoprotein cholesterol level, total cholesterol level, and estimated glomerular filtration
rate.
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of 18% per standard-deviation increase in metabolite levels
(Figure 2).
Cotinine, an alkaloid in tobacco, was the strongest risk-
increasing predictor of death (hazard ratio (HR) per standard-
deviation (SD) increase = 1.40, 95% confidence interval (CI):
1.23, 1.59). Gamma-glutamyl-leucine, a dipeptide composed
of γ-glutamate and leucine, was the most significant metabo-
lite and the strongest risk-decreasing predictor (HR per SD =
0.80, 95% CI: 0.74, 0.87). Uridine, one of the 5 standard
nucleosides, also showed a modest protective association
with death (HR per SD = 0.86, 95%CI: 0.79, 0.92). A metab-
olite risk score based on the weighted levels of the 9 metab-
olites showed a large effect size for the risk of death, where
higher quartiles of the risk score were related to higher risk of
death (P for trend < 0.001; Table 2). The concordance prob-
ability for the risk of death was also noticeably increased by
adding the metabolite risk score to the traditional risk factors
(bias-corrected Harrell’s C statistic 0.752 vs. 0.730). When
metabolite risk score was added to the traditional risk model,
the net reclassification index based on the 20-year risk cate-
gories (<6%, 6%–20%, and >20%) was improved 7.1% (P <
0.001), whereas the continuous net reclassification index and
the integrated discrimination index were 36.5% (P < 0.001)
and 3.7% (P < 0.001), respectively.
Metabolomic association with CVD mortality
Five metabolites (3 named and 2 unnamed) among 3 super-
pathways were identified as being associated (P < 1.23 × 10−4)
with incident CVD mortality using Cox models, after adjust-
ment for demographic factors and traditional risk factors
(Figure 1B; full results shown in Web Table 2), and all of
them showed positive associations with CVD mortality. Two
named metabolites, mannose (HR per SD = 1.33, 95% CI:
1.21, 1.47) and glycocholate (HR per SD = 1.14, 95% CI:
1.07, 1.22), were independently associated with CVDmortal-
ity. Both mannose and glycocholate were significantly related
to all-cause mortality as well, with slightly larger magnitudes
of effect sizes (Figure 2). Mannose, a C-2 epimer of glucose,
had a high correlation with glucose levels (r = 0.86) but was
persistently related to all-cause mortality and CVD mortality
even after glucose levels were accounted for (data not shown).
Similar to glucose (6), mannose showed a nonlinear relation-
ship with mortality, where the third and fourth quartiles had a
higher risk but the second quartile showed the lowest risk
(Web Figure 1). No apparent improvement in the predictive
ability for risk of CVD mortality was observed by adding
mannose and glycocholate to the traditional risk factors (bias-
corrected Harrell’s C statistic 0.790 vs. 0.783).
DISCUSSION
We related the untargeted serummetabolome (n = 204 me-
tabolites) to incident mortality (n = 671 cases) after 22.5 years
of follow-up in a sample of 1,887 ARIC African-American
study participants.We identified 9metabolites that were asso-
ciated with incident all-cause mortality, and 2 of the 9 metab-
olites were also associated with incident CVD mortality.
These associations were independent of other risk factors,
and a metabolite risk score, created by aggregating the infor-
mation from 9 individual metabolites, significantly improved
prediction of incident all-cause mortality.
In a recent targeted metabolomic study of 106 candidate
biomarkers, Fischer et al. (8) reported that 4 biomarkers—
α-1-acid glycoprotein, albumin, very-low-density lipoprotein
particle size, and citrate—were predictive of all-cause mortality
as well as CVD mortality. Three of these biomarkers—α-1-
acid glycoprotein, albumin, and very-low-density lipoprotein
particle size—are large molecules or molecular complexes,
which were not measured by our methods. Citrate was mea-
sured in our study but was later excluded from the analysis
due to high variability as measured 4–6 weeks apart (reliabil-
ity coefficient = 0.375).We explored the association of citrate
with all-cause mortality, and no significant association was
observed amongAfricanAmericans inARIC (data not shown).
A potential explanation may be the presence of population-
specific effects on mortality or fluctuation of levels over time,
as indicated by citrate’s overall high variability.
In this study, 7 metabolites were shown to have positive
associations with all-cause mortality. Cotinine, a metabolite
of nicotine found in tobacco, was the strongest predictor of
mortality. It is well-established that smoking increases risk
of death (18, 19). In our study, we found that about 13% of
non–current smokers had detectable cotinine levels, and in a
stratified analysis, cotinine was strongly associated with high
risk of death for both non–current and current smokers (data
not shown). The findings presented here suggest a dose-
response relationship between cotinine and death, in addition
to overt smoking status. Glucose, a biomarker of diabetes, has
been shown to have a J-shaped association with mortality (6,
20). Mannose is a sugar monomer, which can be formed from
glucose. Here we report that mannose, similar to glucose, has
a J-shaped association with all-cause mortality. Interestingly,
its association with mortality persists after accounting for
glucose levels. Mannose is also involved in protein glycosyl-
ation (21), suggesting a mechanistic influence on mortality
outside of hyperglycemia, possibly through the changes in
protein glycosylation that occur in response to inflammation
Table 2. Hazard Ratios for the Association of Metabolite Risk Score
(Quartiles) With Incident All-Cause Mortality Among African
Americans in the ARIC Study, 1987–2011
Quartile of
Metabolic
Risk Scorea
Hazard
Ratiob
95%
Confidence
Interval
Mortality Rate
(per 1,000
Person-Years)
1 1.00 Referent 7.60
2 1.34 1.01, 1.79 12.00
3 2.02 1.53, 2.66 20.33
4 3.24 2.42, 4.33 36.62
Abbreviation: ARIC, Atherosclerosis Risk in Communities.
a Crude P for trend < 0.001 (calculated as a linear trend in quartile
number).
b Hazard ratio for all-cause mortality generated from Cox proportional
hazards regression.Covariateswere: age, sex, bodymass index, systolic
blood pressure, antihypertensive medication use, diabetes status, cur-
rent smoking status, prevalent cardiovascular disease status, plasma
high-density lipoprotein cholesterol level, total cholesterol level, and
estimated glomerular filtration rate from baseline measurement.
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(22–24). Zheng et al. (25) previously reported that a metab-
olomic pattern consisting of 16 metabolites derived from
principal component analysis was associated with risk of de-
veloping hypertension, and elevated blood pressure levels are
risk factors for all-cause mortality (26). In the present study,
we observed that 2 metabolites, pregnendiol disulfate and
α-hydroxyisovalerate, which are involved in the previously
reported hypertension-related metabolomic pattern, increased
the risk of all-cause mortality. Glycocholate is an indirect
cholesterol-derived bile acid (27), and little is known about its
biological function. Total cholesterol levels have an impact on
all-cause mortality (28, 29); however, the correlation between
glycocholate and cholesterol in our study was low (r =−0.09).
N-acetylalanine is an amino acid and andro-steroid mono-
sulfate 2 is an androgen metabolite in serum, while their bio-
logical functions are largely unknown. Here we report that
high levels of N-acetylalanine and andro-steroid monosulfate
2 have modest associations with all-cause mortality in African
Americans; however, their biological functions and health
effects need further investigation.
In contrast to the 6 metabolites mentioned above, uridine
and γ-glutamyl-leucine were inversely associated with all-
cause mortality. Uridine is a pyrimidine nucleoside involved
in glycolysis. Studies have demonstrated that uridine has a
protective effect on neurological disorders by enhancing gly-
colytic energy production (30, 31), and it protects neurons
against ischemic insult-induced neuronal death in animal
models (32). Gamma-glutamyl-leucine, a dipeptide com-
posed of γ-glutamate and leucine, is an incomplete break-
down product of protein digestion/catabolism. In animal
studies, an increased level of γ-glutamyl-leucine is an indica-
tor of an anti-obesogenic metabolism (33). Obesity has been
associated with higher risk of all-cause mortality (34), and
our findings suggested that an anti-obesogenic metabolism
may be beneficial for overall health and longevity.
Studies have shown that inflammatory and hyperglycemia
biomarkers, such as B-type natriuretic peptide, C-reactive pro-
tein, cardiac troponins, and glucose, are associated with the
risk of all-cause mortality, as well as CVD mortality (3, 6,
35). CVD mortality is the largest component of age-adjusted
mortality in the United States (1). In our study, all metabolites
identified as being associated with all-cause mortality showed
nominal significance with CVD mortality, while two of them,
mannose and glycocholate, reached our stringent significance
threshold. Mannose and glycocholate are involved in glucose
and cholesterol metabolisms, 2 key factors that regulate the
prognosis and progression of CVD (36).
To our knowledge, this is the first population-based un-
targeted metabolomics study to identify novel biomarkers
for mortality in African Americans. However, potential limita-
tions of this study deserve consideration. We limited the anal-
yses to those metabolites with few missing values and high
reliability coefficients; therefore, possible associations be-
tween the excluded metabolites and mortality need further in-
vestigation. The participants in the present study were African
Americans; it is yet unknown whether our findings could be
generalized to other ethnic groups. The focus of this study was
all-cause mortality and CVDmortality; future studies on death
from other causes, such as cancer, are warranted. Our study ap-
plied untargeted metabolomic technologies, which capture
both named and unnamed metabolites. Besides named metab-
olites, we identified several unnamed metabolites associated
with all-cause and CVDmortality. Little is known about these
unnamed metabolites, and their chemical structures need fur-
ther exploration in order to obtain critical insight into patho-
genic mechanisms of mortality.
In summary, we found 9 metabolites that were associated
with all-cause mortality, and 2 of them were associated
with CVD mortality. In addition, the metabolite risk score,
a collective measurement of 9 individual metabolites,
prominently enhanced the prediction of all-cause mortality.
Our results highlight the importance of evaluating metabo-
lomic biomarkers in a prospective cohort study to help
identify novel molecular mechanisms that influence human
health.
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